Publications:

Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread.

Scientific Reports

Hsu, Hung-Chih HC; Huang, Kuo-Cheng KC; Chen, Wei-Shone WS; Jiang, Jeng-Kai JK; Yang, Shung-Haur SH; Wang, Huann-Sheng HS; Chang, Shih-Ching SC; Lan, Yuan-Tzu YT; Lin, Chun-Chi CC; Lin, Hung-Hsin HH; Huang, Sheng-Chieh SC; Cheng, Hou-Hsuan HH; Yang, Tsai-Sheng TS; Chen, Chien-Chih CC; Chao, Yee Y; Teng, Hao-Wei HW

Publication Date: 2021-07-28

Variant appearance in text: NRAS: V109C

PubMed Link: 34321583

Variant Present in the following documents:

• Main text

View BVdb publication page